OBJECTIVE: Zidovudine is a well known cause of macrocytosis. However, many HIV-infected patients develop macrocytosis even though they do not receive zidovudine. The aim of this case-control study was to evaluate other causes of high mean corpuscular volumes (MCV) in HIV infected patients. METHODS: Thirty patients with a MCV > or = 100 fl (cases) were compared to 60 randomly selected controls with MCV A< or = 99 fl, none of them receiving zidovudine. RESULTS: Sex ratio, age, mean CD4, prevalence of alcohol abuse and liver disease were similar in both groups. Vitamin B12 or folic acid levels were not decreased in patients with macrocytosis. In contrast, there was an association between macrocytosis and use of stavudine alone or in combination with another antiviral drug (28/30 cases, 15/60 controls, odds ratio 40.6 (95% confidence interval 5.1-325.2), P< 0.001). The haemoglobin concentration among cases (mean 13.5 g/dl) was similar to that of controls (mean 13.0 g/dl). CONCLUSIONS: Stavudine use increase the risk of macrocytosis more than 40-fold in HIV-infected patients who do not receive zidovudine. None of the stavudine-treated patients, however, developed anaemia or had to interrupt treatment because of this side effect.
OBJECTIVE:Zidovudine is a well known cause of macrocytosis. However, many HIV-infectedpatients develop macrocytosis even though they do not receive zidovudine. The aim of this case-control study was to evaluate other causes of high mean corpuscular volumes (MCV) in HIV infectedpatients. METHODS: Thirty patients with a MCV > or = 100 fl (cases) were compared to 60 randomly selected controls with MCV A< or = 99 fl, none of them receiving zidovudine. RESULTS: Sex ratio, age, mean CD4, prevalence of alcohol abuse and liver disease were similar in both groups. Vitamin B12 or folic acid levels were not decreased in patients with macrocytosis. In contrast, there was an association between macrocytosis and use of stavudine alone or in combination with another antiviral drug (28/30 cases, 15/60 controls, odds ratio 40.6 (95% confidence interval 5.1-325.2), P< 0.001). The haemoglobin concentration among cases (mean 13.5 g/dl) was similar to that of controls (mean 13.0 g/dl). CONCLUSIONS:Stavudine use increase the risk of macrocytosis more than 40-fold in HIV-infectedpatients who do not receive zidovudine. None of the stavudine-treated patients, however, developed anaemia or had to interrupt treatment because of this side effect.
Authors: Sapna Gangaputra; Partho S Kalyani; Amani A Fawzi; Mark L Van Natta; Larry D Hubbard; Ronald P Danis; Jennifer E Thorne; Gary N Holland Journal: Am J Ophthalmol Date: 2011-10-22 Impact factor: 5.258
Authors: Asha R Kallianpur; Quan Wang; Peilin Jia; Todd Hulgan; Zhongming Zhao; Scott L Letendre; Ronald J Ellis; Robert K Heaton; Donald R Franklin; Jill Barnholtz-Sloan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; J A McCutchan; Igor Grant Journal: J Infect Dis Date: 2015-12-21 Impact factor: 5.226
Authors: Benjamin J Eckhardt; Robert S Holzman; Candice K Kwan; Jonathan Baghdadi; Judith A Aberg Journal: AIDS Patient Care STDS Date: 2012-02-10 Impact factor: 5.078
Authors: Laurence Slama; Frank J Palella; Alison G Abraham; Xiuhong Li; Corinne Vigouroux; Gilles Pialoux; Lawrence Kingsley; Jordan E Lake; Todd T Brown Journal: J Antimicrob Chemother Date: 2014-08-04 Impact factor: 5.790
Authors: Deanna Cettomai; Judith K Kwasa; Gretchen L Birbeck; Richard W Price; Craig R Cohen; Elizabeth A Bukusi; Caroline Kendi; Ana-Claire L Meyer Journal: Muscle Nerve Date: 2013-08-27 Impact factor: 3.217
Authors: Joseph O Mugisha; Katherine Donegan; Sarah Fidler; Gita Ramjee; Andrew Hodson; David T Dunn; Kholoud Porter; Pontiano Kaleebu Journal: Open AIDS J Date: 2012-05-31
Authors: Peter S Kim; Christian Woods; Patrick Georgoff; Dana Crum; Alice Rosenberg; Margo Smith; Colleen Hadigan Journal: Diabetes Care Date: 2009-06-05 Impact factor: 19.112